Use of pridopidine for treating anxiety and depression

1 . A method of treating depression or anxiety in a human subject by administering a composition comprising an amount of pridopidine, or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the depression or anxiety is not caused by Huntington's Disease.

3 . The method of claim 1 , wherein the depression or anxiety is associated with cognitive deficits.

4 . The method of claim 2 , wherein the depression or anxiety is associated with cognitive deficits.

5 . The method of claim 3 , wherein the cognitive deficits comprise memory loss, loss of higher reasoning, forgetfulness, learning disabilities, concentration difficulties, or decreased intelligence.

6 . The method of claim 4 , wherein the cognitive deficits comprise memory loss, loss of higher reasoning, forgetfulness, learning disabilities, concentration difficulties, or decreased intelligence.

7 . The method of claim 1 , wherein the composition comprises between 22.5 mg/day and 315 mg/day of pridopidine or pharmaceutically acceptable salt thereof.

8 . The method of claim 1 , wherein the composition is administered once daily or twice daily.

9 . The method of claim 1 , wherein the composition is administered orally.

10 . The method of claim 1 , wherein the pharmaceutically acceptable salt of pridopidine comprises pridopidine hydrochloride, hydrobromide, nitrate, perchlorate, phosphate, sulphate, formate, acetate, aconate, ascorbate, benzenesulphonate, benzoate, cinnamate, citrate, embonate, enantate, fumarate, glutamate, glycolate, lactate, maleate, malonate, mandelate, methanesulphonate, naphthalene-2-sulphonate, phthalate, salicylate, sorbate, stearate, succinate, tartrate or toluene-p-sulphonate salt.

11 . The method of claim 10 , wherein the salt comprises hydrochloride salt.

12 . The method of claim 1 , wherein the composition comprises an amount of pridopidine base.